Physician profile
Scott Seifert
NPI 1396159711
$2,535.81
in general payments reported to CMS, 2019-2025
19 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $101 · 2021: $118 · 2022: $175 · 2023: $390 · 2024: $1,096 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665 · Travel and Lodging: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,665.33 |
| Travel and Lodging | $352.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,128.61 | 2022-2025 | Da Vinci Surgical System |
| Lilly USA, LLC | $324.90 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $157.63 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $137.78 | 2021-2025 | Xolair |
| Philips North America LLC | $137.40 | 2020-2025 | Vest Therapy Und |
| Inari Medical, INC. | $131.33 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $122.77 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.35 | 2023-2025 | Jardiance, Tradjenta |
| Regeneron Healthcare Solutions, INC. | $56.77 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $56.42 | 2025 | Tezspire, Airsupra |
| Genzyme Corporation | $40.82 | 2025 | |
| Electromed, INC. | $35.53 | 2025 | Smartvest |
| Viatris Specialty LLC | $24.89 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $18.33 | 2024 | Aralast |
| Azurity Pharmaceuticals, INC. | $17.90 | 2025 | Alvesco |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.17 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.91 | 2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $14.21 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Seifert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.